RxDoctor Payments Data

Christopher Huang, MD

Gastroenterology · Boston, MANPI 1205894409

Payments from drug & device makers

$29,690in general payments, 2019–2025

Across 50 payments — averaging $593.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$13K
  • Olympus Corporation Of The Americas$11K
  • Chugai Pharmaceutical Co., Ltd.$5K
  • GSK$959
  • Boston Scientific$38
$64,063in research payments, 2019–2025

Across 22 payments — averaging $2911.96 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • GSK$64K

What the payments were for

  • Food & beverage$1141%
  • Education$11,13899%

General payments by program year

22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$29,690 in reported general payments places this provider in the 80th percentile of 579 gastroenterology providers in Massachusetts.

See all gastroenterology providers in Massachusetts

Medicare billing

Part B allowed, 2024
$46,880
Medicare patients
193
Services billed
284

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide46$26,408
Dexlansoprazole DrDexlansoprazole26$7,058
Erythromycin Ethylsuccinate15$2,392
Colestipol Hcl12$1,319
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl65$1,174
Dicyclomine Hcl46$946
Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl35$733
Hydromorphone Hcl13$702
Ondansetron OdtOndansetron16$566
Pantoprazole Sodium25$338
Omeprazole17$257
LoperamideLoperamide Hcl16$236
Famotidine24$180
Oxycodone Hcl13$165

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$12,880$26,40846 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 579 gastroenterology providers in Massachusetts.

Other gastroenterology in Boston

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →